Newsfeeds - Spark Newswire

3 minute read

34 Stocks Moving In Tuesday’s Mid-Day Session

Today, 10:50 PM

Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.8% to $0.3830. Exicure’s Audit Committee recently concluded that Grant Corbett misreported raw data from certain R&D experiments related to XCUR-FXN preclinical program.

ADGI

2 minute read

Mid-Morning Market Update: Markets Mostly Lower; Producer Prices Rise 0.8% In November

By Lisa Levin

Today, 10:50 PM

Following the market opening Tuesday, the Dow traded up 0.06% to 35,673.60 while the NASDAQ fell 1.08% to 15,247.22. The S&P also fell, dropping 0.57% to 4,642.29.

ADGI

4 minute read

Cabaletta Bio Reports Top-line Biologic Activity Data From Two Lowest Dose Cohorts In DesCAARTes Trial In Patients With Mucosal Pemphigus Vulgaris

By Bill Haddad

Today, 10:50 PM

Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today

CABA

7 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For December 8, 2021

By Benzinga Insights

Today, 10:50 PM

ALLE

1 minute read

Cabaletta Posts Cell Therapy Data From Third Cohort Of Autoimmune Skin Disorder Trial

By Vandana Singh

Today, 10:50 PM

Cabaletta Bio Inc (NASDAQ:CABA) has announced 28-day clinical data from the third dose cohort (500 million DSG3-CAART cells) in the DesCAARTes…

CABA

1 minute read

Cabaletta Bio Q3 EPS $(0.45) Beats $(0.50) Estimate

By Benzinga Newsdesk

Today, 10:50 PM

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.50) by 10 percent. This is a 25 percent decrease over losses of $(0.36) per share from the same

CABA

2 minute read

FDA
News

Cabaletta Bio Reports Clinical Data From 3rd Dose Cohort In DesCAARTes Trial In Patients With mPV

By Benzinga Newsdesk

Today, 10:50 PM

CABA

3 minute read

Cabaletta Bio Announces Presentation Of Preclinical Data Supporting PLA2R-CAART As Potential Precision Therapy For Antigen-Specific B Cell Depletion An PLA2R Membranous Nephropathy At ASN Kidney Week 2021

By Benzinga Newsdesk

Today, 10:50 PM

Cabaletta Bio, Inc.

CABA

3 minute read

30 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 10:50 PM

Gainers Kadmon Holdings, Inc. (NASDAQ: KDMN) shares jumped 72.6% to $9.15. Sanofi announced Wednesday it has agreed to acquire New York-based biopharma Kadmon in a $1.9 billion all-cash deal.

ALEC

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

Today, 10:50 PM

Gainers

ANPC